News headlines about Illumina (NASDAQ:ILMN) have trended positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than 6,000 news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Illumina earned a daily sentiment score of 3.00 on their scale. InfoTrie also assigned news stories about the life sciences company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Illumina’s score:

Shares of NASDAQ ILMN traded down $16.04 during midday trading on Tuesday, hitting $334.21. The stock had a trading volume of 1,654,825 shares, compared to its average volume of 942,396. The stock has a market capitalization of $49.61 billion, a P/E ratio of 83.55, a price-to-earnings-growth ratio of 2.50 and a beta of 1.08. Illumina has a fifty-two week low of $207.51 and a fifty-two week high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.26. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The company had revenue of $853.00 million during the quarter, compared to analysts’ expectations of $825.65 million. During the same period last year, the firm earned $1.11 EPS. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. Equities research analysts forecast that Illumina will post 5.75 earnings per share for the current fiscal year.

A number of brokerages have recently commented on ILMN. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. Barclays increased their target price on Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research note on Wednesday, October 24th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank raised their price objective on Illumina to $350.00 and gave the stock a “buy” rating in a research report on Friday, October 12th. Finally, ValuEngine downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $330.94.

In other Illumina news, Director Robert S. Epstein sold 1,346 shares of Illumina stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $345.14, for a total transaction of $464,558.44. Following the transaction, the director now directly owns 7,139 shares in the company, valued at $2,463,954.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Francis A. Desouza sold 2,100 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $369.61, for a total value of $776,181.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,428 shares of company stock worth $23,533,478. Corporate insiders own 0.54% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Article: Different Types of Derivatives

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with's FREE daily email newsletter.